Next week, C-Path's Critical Path for Alzheimer's Disease Consortium team will be on site at the Alzheimer's Association® International Conference (#AAIC24) in Philadelphia! Visit us at booth 1340 to connect with our experts: Klaus Romero, Diane Stephenson, Martijn Muller, Yashmin Karten, Anna-Marika Bauer, MRA, Colleen Jacobsen and Eileen Priest. CPAD accelerates the development of patient-centric therapies for Alzheimer's disease by creating new, regulatory-endorsed drug development tools. These tools, built on the latest scientific insights and supported by a comprehensive database of patient-level clinical trial data, enhance our expertise in clinical trial design. We look forward to discussing how we can collaborate to advance Alzheimer's research and improve patient outcomes. See you at #AAIC24! #CPath #Alzheimers #drugdevelopment #datasharing #clinicaltrials #globalhealth #collaboration #AD
Critical Path Institute (C-Path)
Research Services
Tucson, AZ 7,824 followers
Advancing Drug Development. Improving Lives. Together.
About us
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
- Website
-
http://www.c-path.org/
External link for Critical Path Institute (C-Path)
- Industry
- Research Services
- Company size
- 51-200 employees
- Headquarters
- Tucson, AZ
- Type
- Nonprofit
- Founded
- 2005
- Specialties
- creating collaborations with regulators, patient advocacy groups and the regulated pharmaceutical industry, accelerated development of safer, new medical products, faster, safer, and smarter medical product development, and public private partnership
Locations
-
1840 E River Rd # 100
Tucson, AZ 85718, US
-
Barbara Strozzilaan 201 1083 HN
Amsterdam, NL
Employees at Critical Path Institute (C-Path)
-
Deb Discenza (she/her/hers)
-
Thomas Morel
Global Patient-Centred Outcomes Research & Policy Lead at UCB
-
Huong Huynh Reagan
Regulatory Director | Regulatory endorsements of drug development tools | Cross-functional collaborations | Diverse disease portfolio | Lead people;…
-
Hannah Blau
Data Scientist ∙ ML / NLP Engineer ∙ Listener Extraordinaire ∙ She who does not let stuff fall through the cracks
Updates
-
We are proud to be part of a significant advancement in the fight against Parkinson's disease today. What an honor to collaborate with the Digital Medicine Society (DiMe) and The Michael J. Fox Foundation for Parkinson's Research on the expansion of the Library of Digital Measurement Products. This expansion now includes 94 additional digital solutions, supporting Parkinson's disease research, fostering innovation, and improving patient care worldwide. C-Path's Critical Path for Parkinson’s Consortium is dedicated to improving the lives of those affected by Parkinson's disease by accelerating drug development and consistently incorporating the patient voice throughout the process. 🔗 Explore the expanded library here: https://bit.ly/3A0Mers 🔗Learn more about the Critical Path for Parkinson's Consortium here: https://lnkd.in/gH7vqiW4 Klaus Romero Diane Stephenson Martijn Muller #CPath #DiMe #MichaelJFox #Parkinsons #ParkinsonsResearch #Collaboration #DigitalHealth #collaboration #datasharing #drugdevelopment
🎉 DATAcc by DiMe is proud to announce a significant milestone in the fight against Parkinson's disease (PD)! 🤝 With our partners at The Michael J. Fox Foundation for Parkinson's Research and the Critical Path Institute (C-Path)'s Critical Path for Parkinson’s consortium, we have expanded our Library of Digital Measurement Products by integrating 94 additional digital solutions that support Parkinson's disease (PD) research and care. This collaboration enhances the existing resources of the library, providing a more comprehensive toolset for the PD community. 🛠️ Due to diverse and fluctuating symptoms, designing patient-centric digital interventions and therapeutics for PD can be challenging. Sensor-based digital health technologies (sDHTs) bridge this gap by enabling remote and frequent measurement of PD symptoms, supporting early intervention, innovative treatments, and improved patient outcomes. 📚 The expanded library supports clinicians, researchers, and developers with validated tools and streamlined evidence to advance digital health strategies and accelerate the path to improved patient outcomes. 🌐 As part of the expansion of digital solutions to support PD research and care, we have also enhanced the library with a user-friendly interface and intuitive user journey to enable faster, more efficient access to tailored digital health solutions. The library features meaningful concepts of physical activity (PA), Parkinson’s Disease (PD), Sleep, and Alzheimer’s disease and related dementias (ADRD). 💪 This collaboration represents a pivotal step forward in PD research and patient care and exemplifies the power of working collectively to address complex health challenges. We are grateful to our partners for their collaboration and shared vision in advancing digital health solutions for Parkinson's disease. 🔗 Explore the expanded library here: https://bit.ly/3A0Mers
-
-
C-Path's Critical Path for Lysosomal Diseases Consortium today proudly announced the addition of Chiesi Group as a member. The partnership marks a significant milestone in the CPLD’s mission to accelerate drug development for lysosomal diseases and improve the lives of individuals affected by these rare conditions. “We are pleased to join the CPLD Consortium and take part in this important collaborative effort to help address the significant unmet medical needs affecting people living with LDs,” said Giacomo Chiesi, MBA, head of Chiesi Global Rare Diseases. “Driven by our deep commitment to advancing sustainable therapeutic options for rare diseases including LDs, we look forward to working closely with the consortium to support innovation and progress in LD drug development.” Learn the full details here: https://lnkd.in/gGSawnJq Amanda Klein Krista Casazza #CPath #ChiesiGroup #raredisease #lysosomal #collaboration #drugdevelopment #datasharing #globalhealth
-
-
C-Path’s T1D Consortium and Quantitative Medicine Program assisted the team University of Florida with the creation of a clinical trial simulation tool and corresponding article titled "Type 1 Diabetes Prevention Clinical Trial Simulator: Case Reports of Model-informed Drug Development Tool." The article was recently published in CPT: Pharmacometrics & Systems Pharmacology and focuses on the development of a disease progression model-based CTS tool using individual-level data collected from multiple sources. The goal of this tool is to help design more efficient clinical trials that will prevent or delay the onset of T1D. Within the article, the tool is described in depth along with instructions on how to use the tool and case studies. ⏩ Access the article here: https://lnkd.in/gd8mefC3 ⏩ The web-based tool is publicly available here: https://lnkd.in/g_aFYKWk ⏩ Information on C-Path's T1DC here: https://lnkd.in/g9s6mzJ7 Juan Francisco Morales Jagdeep Podichetty, PhD Jackson Burton Klaus Romero Inish O'Doherty, Ph.D. Sarah Kim Sarah David ASCPT Journal Family #CPath #T1D #ASCPTJournalFamily #PSPJournal #drugdevelopment #datasharing #collaboration #globalhealth #diabetes
-
-
Interested in C-Path updates? Be sure to subscribe at https://lnkd.in/gyhN4vac For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together. #CPath #drugdevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience
-
Thank you to BizTucson Magazine and News 4 Tucson - KVOA for featuring C-Path in their "The World is Watching Tucson" feature and coverage. As we celebrate 20 years of impact and collaborations, C-Path remains a trusted and neutral partner, leading efforts to generate tools and solutions that de-risk and accelerate the drug development process. https://lnkd.in/gfNBVyT8 #CPath #BizTucson #KVOA #Tucson #Arizona #drugdevelopment #collaboration #partnership #datasharing
Critical Path Institute plays a major role in advancing drug development globally
kvoa.com
-
C-Path’s Global Impact Conference is THE event that drug developers cannot afford to miss. Hosted this September 9-11, in Washington, D.C., we are thrilled to announce the first of our impressive lineup of speakers. These experts bring unparalleled insights across various diseases and therapeutic areas. With a roster featuring the best and brightest minds in drug development, and with the early-bird 🦅 registration rate expiring at 11:59 p.m. ET, Monday, July 22, why wait? 🔗 Register now and learn more: https://lnkd.in/g4TqwJVR. ▶ Join FDA Center For Drug Evaluation and Research Director Patrizia Cavazzoni, M.D., for a focused session on how we can maximize the impact of CDER-led efforts for clinical trial modernization, while retaining scientific and clinical rigor. ▶ Teresa Buracchio, MD, Director of the Office of Neuroscience, CDER, FDA, will be a panelist discussing biology-based disease staging approaches. ▶ Naomi Knoble, PhD, Ph.D., Associate Director of Rare Disease Measurement Science in the Division of Clinical Outcome Assessment, Office of New Drugs, CDER, FDA, will join us for the fireside chat, “Navigating the patient-focused drug development roadmap: update on the RD-COA Resource.” We look forward to seeing you at #CGIC2024! Klaus Romero Kristen Swingle Kevin Perkins Collin Hovinga Diane Stephenson Joseph Hedrick #CPath #CGIC2024 #GlobalImpactConference #drugdevelopment #datasharing #collaboration #neurology #pediatrics #raredisease
-
C-Path’s Huong Huynh Reagan and Smith Heavner, PhD, RN will be teaching as part of the University of Arizona Law, Health Law & Policy Program’s Regulatory Science Certificate courses. For those interested in the regulatory process in drug development, this program offers an excellent pathway. Applications for the fall semester are due by August 1. Register now: https://lnkd.in/gdvYkXZg #CPath #drugdevelopment #datasharing #regulatoryscience
Fall 2024 is nearly here. Our online courses cover a range of cutting-edge health law issues, including the latest regulations in drug development, health information privacy, and healthcare delivery. We also take a deep dive on ethical and legal issues emerging with using technology to care for our growing aging population. Apply to one of the four Certificates in Health Law and Policy and enroll in our Fall 2024 courses before August 1st. https://lnkd.in/gdvYkXZg #healthlaw #healthpolicy #regulatoryscience #compliance #eldercare #aginglaw #healthinformation #healthprivacy #drugdevelopment #healthproviders #onlinecourses #onlinecertificate #HIPAA
-
-
TOMORROW: The Influential Role of Patient Advocacy Groups in Registry Data Efforts Join us on Thursday, July 18, at 12 p.m. ET for an insightful webinar hosted by C-Path's Mitochondrial and Inherited Metabolic Diseases Task Force. Discover how patient advocacy groups are pivotal in driving registry data efforts for mitochondrial and inherited metabolic diseases, ensuring that patient experiences and outcomes are central to research and regulatory decision-making. Our presenters include: Sophia Zilber 🌺Board Member and Patient Registry Director, Cure Mito Foundation. Sophia brings over 20 years of experience in drug development and clinical data analysis, leading the global Leigh syndrome patient registry at the Cure Mito Foundation. Elizabeth Reynolds, Co-Founder and Executive Director, The Champ Foundation. Dr. Reynolds has spearheaded over $2 million in research grants for Single Large-scale mtDNA Deletion Syndromes and co-leads a multi-site Natural History Study and patient-registry. Amanda Klein, Executive Director, Critical Path for Lysosomal Diseases and the Alpha-1 Antitrypsin Deficiency Consortia at C-Path. Dr. Klein leads initiatives to accelerate drug development for mitochondrial and inherited metabolic diseases and is a key figure in the RDCA-DAP initiative. Don’t miss this opportunity to learn from experts about the crucial role of patient advocacy in advancing research and healthcare outcomes. 🔗 Register now to secure your spot: https://lnkd.in/eNExmF9R #CPath #PatientAdvocacy #MitochondrialDiseases #Webinar #HealthcareInnovation #DrugDevelopment #collaboration #datasharing
-
-
JOIN US TOMORROW, July 18, for an in-depth look at the key considerations around the use of Bring Your Own Device (BYOD) approaches to electronic clinical outcome assessment data collection in clinical trials, developed and presented by members of the BYOD Project Team as part of the eCOA Consortium and PRO Consortium’s eCOA: Getting Better Together Initiative. Register now: https://lnkd.in/enx2u4Xb Karl McEvoy Kelly Dumais Chris Barden Heather Romero Scottie Kern eCOA members, include: ActiGraph Evinova Clario ICON plc Inspired Health IQVIA Kayentis Koneksa Mapi Research Trust Medable, Inc Medidata Solutions Medrio ObvioHealth Parexel Red Nucleus RWS Group Signant Health Suvoda TransPerfect Life Sciences uMotif WCG YPrime #CPath #eCOA #DHT #ACT #eCOAC #globalhealth #collaboration #drugdevelopment #datasharing #clinicaltrials
-